HA 1077, Dihydrochloride Calbiochem,103745-39-7

别名

HA 1077, Dihydrochloride - CAS 103745-39-7 - Calbiochem,Fasudil, (5-Isoquinolinesulfonyl)homopiperazine, 2HCl, PKG Inhibitor VII

一般描述

A cell-permeable, reversible, and ATP-competitive Ca2+ antagonist with anti-vasospastic properties. Inhibits protein kinase A (Ki = 1.6 μM), protein kinase G (Ki = 1.6 μM), and myosin light chain kinase (Ki = 3.6 μM). Also reported to potently inhibit Rho-associated kinase (ROCK; IC50 = 10.7 μM). Prevents apoptosis and enhances the survival and cloning efficiency of dissociated hES cells without affecting their pluripotency. A cell-permeable, reversible, and ATP-competitive Ca2+ antagonist with anti-vasospastic properties. Inhibits protein kinase A (Ki = 1.6 μM), protein kinase G (Ki = 1.6 μM), and myosin light chain kinase (Ki = 36 μM). Also reported to potently inhibit Rho-associated kinase (ROCK; IC50 = 10.7 μM). Prevents apoptosis and enhances the survival and cloning efficiency of dissociated hES cells without affecting their pluripotency.

生化/生理作用

Cell permeable: yes Primary Target
PKA Product competes with ATP. Reversible: yes Target IC50: 10.7 μM inhibiting Rho-associated kinase (ROCK) Target Ki: .6 μM, 1.6 μM, 36 μM, inhibiting protein kinase A, protein kinase G, myosin light chain kinase, respectively

重悬

Following reconstitution, refrigerate (4°C). Aqueous stock solutions are stable for up to 6 months at 4°C.

其他说明

Watanabe, K., et al. 2007. Nature Biotech.25, 681.
Sw?rd, K., et al. 2000. J. Physiol.522, 33.
Takizawa, S., et al. 1993. Eur. J. Pharmacol. 250, 431.
Seto, M., et al. 1991. Eur. J. Pharmacol.195, 267.
Shirotani, M., et al. 1991. J. Pharmacol. Exp. Ther.259, 738.
Asano, T., et al. 1990. Eur. J. Pharmacol.190, 365.
Sasaki, Y., and Sasaki, Y. 1990. Biochem. Biophys. Res. Commun.171, 1182.
Asano, T., et al. 1989. Br. J. Pharmacol. 98,1091.